Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results
Guardant Health (GH) reported strong preliminary Q4 and full-year 2024 results, with total revenue reaching approximately $200 million in Q4 (29% increase) and $737 million for the full year (31% increase). The company saw significant growth in test volumes, with 57,300 oncology clinical tests (24% increase) and 11,050 biopharma tests (16% increase) in Q4.
The Shield screening program reported approximately 6,400 tests with revenue of $4 million. For the full year, the company conducted 206,700 oncology clinical tests and 40,500 biopharma tests, showing increases of 20% and 35% respectively. Free cash flow was negative $84 million in Q4 and negative $275 million for 2024. The company maintained a strong cash position of $944 million as of December 31, 2024.
Guardant Health (GH) ha riportato risultati preliminari solidi per il quarto trimestre e per l'intero anno 2024, con entrate totali che hanno raggiunto circa $200 milioni nel Q4 (aumento del 29%) e $737 milioni per l'anno intero (aumento del 31%). L'azienda ha registrato una crescita significativa nei volumi di test, con 57.300 test clinici oncologici (aumento del 24%) e 11.050 test biopharma (aumento del 16%) nel Q4.
Il programma di screening Shield ha riportato circa 6.400 test con entrate di $4 milioni. Per l'intero anno, l'azienda ha condotto 206.700 test clinici oncologici e 40.500 test biopharma, mostrando aumenti rispettivamente del 20% e del 35%. Il flusso di cassa libero è stato negativo di $84 milioni nel Q4 e negativo di $275 milioni per il 2024. L'azienda ha mantenuto una posizione di cassa solida di $944 milioni al 31 dicembre 2024.
Guardant Health (GH) informó resultados preliminares sólidos para el cuarto trimestre y para todo el año 2024, con ingresos totales que alcanzaron aproximadamente $200 millones en el Q4 (aumento del 29%) y $737 millones para el año completo (aumento del 31%). La empresa vio un crecimiento significativo en los volúmenes de pruebas, con 57,300 pruebas clínicas de oncología (aumento del 24%) y 11,050 pruebas de biopharma (aumento del 16%) en el Q4.
El programa de detección Shield reportó aproximadamente 6,400 pruebas con ingresos de $4 millones. Para el año completo, la empresa realizó 206,700 pruebas clínicas de oncología y 40,500 pruebas de biopharma, mostrando aumentos del 20% y 35% respectivamente. El flujo de caja libre fue negativo en $84 millones en el Q4 y negativo en $275 millones para el 2024. La empresa mantuvo una sólida posición de efectivo de $944 millones al 31 de diciembre de 2024.
Guardant Health (GH)는 2024년 4분기 및 전체 연도에 대한 강력한 예비 결과를 보고했습니다. 4분기 총 수익은 약 $200백만에 달하며 (29% 증가), 전체 연도 수익은 $737백만에 달했습니다 (31% 증가). 회사는 테스트 볼륨에서 뚜렷한 성장을 보였으며, 57,300개의 종양학 임상 테스트 (24% 증가)와 11,050개의 생물의약품 테스트 (16% 증가)를 기록했습니다.
Shield 스크리닝 프로그램은 약 6,400개의 테스트를 보고하고, $4백만의 수익을 기록했습니다. 전체 연도 동안 회사는 206,700개의 종양학 임상 테스트와 40,500개의 생물의약품 테스트를 수행했으며, 각각 20%와 35%의 증가를 보였습니다. 자유 현금 흐름은 4분기에 $84백만의 적자가 발생했고, 2024년에는 $275백만의 적자가 발생했습니다. 회사는 2024년 12월 31일 기준으로 $944백만의 강력한 현금 위치를 유지했습니다.
Guardant Health (GH) a annoncé des résultats préliminaires solides pour le quatrième trimestre et pour l'année entière 2024, avec des revenus totaux atteignant environ 200 millions de dollars au Q4 (augmentation de 29%) et 737 millions de dollars pour l'année complète (augmentation de 31%). L'entreprise a connu une croissance significative des volumes de tests, avec 57.300 tests cliniques en oncologie (augmentation de 24%) et 11.050 tests biopharma (augmentation de 16%) au Q4.
Le programme de dépistage Shield a signalé environ 6.400 tests avec des revenus de 4 millions de dollars. Pour l'année complète, l'entreprise a réalisé 206.700 tests cliniques en oncologie et 40.500 tests biopharma, montrant des augmentations respectives de 20% et 35%. Le flux de trésorerie libre a été négatif de 84 millions de dollars au Q4 et négatif de 275 millions de dollars pour 2024. L'entreprise a maintenu une solide position de trésorerie de 944 millions de dollars au 31 décembre 2024.
Guardant Health (GH) berichtete von starken vorläufigen Ergebnissen für das vierte Quartal und das gesamte Jahr 2024, wobei der Gesamtumsatz im Q4 etwa 200 Millionen US-Dollar (29% Zuwachs) und im Gesamtjahr 737 Millionen US-Dollar (31% Zuwachs) betrug. Das Unternehmen verzeichnete ein signifikantes Wachstum bei den Testvolumina, mit 57.300 onkologischen klinischen Tests (24% Zuwachs) und 11.050 Biopharma-Tests (16% Zuwachs) im Q4.
Das Shield-Screening-Programm berichtete von etwa 6.400 Tests mit einem Umsatz von 4 Millionen US-Dollar. Im gesamten Jahr führte das Unternehmen 206.700 onkologische klinische Tests und 40.500 Biopharma-Tests durch, was einem Anstieg von 20% bzw. 35% entspricht. Der freie Cashflow betrug im Q4 -84 Millionen US-Dollar und für 2024 -275 Millionen US-Dollar. Das Unternehmen hielt eine starke Cash-Position von 944 Millionen US-Dollar zum 31. Dezember 2024.
- 31% year-over-year revenue growth to $737 million
- 29% Q4 revenue growth to $200 million
- 35% increase in full-year biopharma test volumes
- Strong cash position of $944 million
- Successful commercial launch of Shield screening program
- Negative free cash flow of $275 million for full year 2024
- Negative free cash flow of $84 million in Q4 2024
Insights
The preliminary Q4 and FY2024 results demonstrate robust financial performance with several key highlights. Total revenue reached
Notable metrics include the
The successful upgrade of Guardant360 LDT to their Smart Liquid Biopsy platform positions the company for continued growth in their core oncology business while expanding into the screening market represents a significant revenue diversification opportunity.
The market implications of these results are compelling, particularly in the precision oncology space. The sustained volume growth in both clinical and biopharma segments indicates strong market adoption and expanding market share. The
The Shield screening test launch represents a strategic entry into the $20+ billion colorectal cancer screening market. Early adoption metrics of 6,400 tests in Q4 suggest positive market reception, though this represents just the beginning of market penetration. The company's commitment to expanding commercial infrastructure for Shield indicates confidence in the market opportunity and could drive significant growth in 2025.
Full year revenue growth of
Fourth quarter 2024 preliminary unaudited financial results
For the three-month period ended December 31, 2024, as compared to the same period of 2023:
-
Total revenue of approximately
$200 million 29% -
Reported approximately 57,300 oncology clinical tests (excluding Shield) and approximately 11,050 biopharma tests, an increase of
24% and16% , respectively -
Reported approximately 6,400 Shield screening tests, with revenue of approximately
$4 million
Full year 2024 preliminary unaudited financial results
For the twelve-month period ended December 31, 2024, as compared to the same period of 2023:
-
Total revenue of approximately
$737 million 31% -
Reported approximately 206,700 oncology clinical tests (excluding Shield) and approximately 40,500 biopharma tests, an increase of
20% and35% , respectively
Preliminary unaudited free cash flow was approximately negative
“2024 was an outstanding year for Guardant. We delivered key milestones across the portfolio and completed the upgrade of Guardant360 LDT onto our Smart Liquid Biopsy platform. We finished the year strong with preliminary full year revenue growth of
“We are extremely pleased with the strong traction and support we saw in the first full quarter of commercial launch of Shield. Given this success, we are focused on rapidly growing our commercial infrastructure to capture the massive opportunity ahead. We look forward to achieving additional milestones in 2025 as we continue driving innovation and growth in our screening business,” said AmirAli Talasaz, co-founder and co-CEO.
Guardant Health has not completed preparation of its financial statements for the fourth quarter or full year of 2024. The revenue, test volumes and free cash flow presented in this release for the fourth quarter and the year ended December 31, 2024, are preliminary and unaudited and are thus inherently uncertain and subject to change as we complete our financial results. The company is in the process of completing its customary year-end close and review procedures as of and for the year ended December 31, 2024, and there can be no assurance that final results for this period will not differ from these estimates. During the preparation of Guardant Health’s consolidated financial statements and related notes as of and for the year ended December 31, 2024, the company’s independent registered public accountants may identify items that could cause final reported results to be materially different from the preliminary financial estimates presented herein.
Upcoming events
Guardant Health plans to report its fourth quarter and full year audited financial results for the period ended December 31, 2024, during its February 2025 earnings call.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2023, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
Source: Guardant Health, Inc.
Reconciliation of Free Cash Flow to Net Cash Used in Operating Activities
(unaudited)
(in millions) |
|||||||||||||||
|
Three Months Ended December 31, |
|
Twelve Months Ended December 31, |
||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
|
|
|
|
|
|
|
|
||||||||
Net cash used in operating activities |
$ |
(65 |
) |
|
$ |
(79 |
) |
|
$ |
(240 |
) |
|
$ |
(325 |
) |
Purchases of property and equipment |
|
(19 |
) |
|
|
(4 |
) |
|
|
(35 |
) |
|
|
(20 |
) |
Free cash flow |
$ |
(84 |
) |
|
$ |
(83 |
) |
|
$ |
(275 |
) |
|
$ |
(345 |
) |
|
|
|
|
|
|
|
|
||||||||
Supplemental Cash Flow Investing and Financing Activities
During the three-month period ended December 31, 2024, the Company sold a portion of its investment in Lunit, Inc., and received sales proceeds of
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113396781/en/
Investor Contact:
Zarak Khurshid
investors@guardanthealth.com
Media Contact:
Melissa Marasco
press@guardanthealth.com
+1 650-647-3711
Source: Guardant Health, Inc.
FAQ
What was Guardant Health's (GH) revenue growth in 2024?
How many oncology clinical tests did GH perform in Q4 2024?
What was GH's cash position at the end of 2024?
How did GH's Shield screening program perform in Q4 2024?
What was Guardant Health's free cash flow for full year 2024?
